Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study

In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of Tislelizumab combined with platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.

Trial Details

NCT ID
NCT07085182
Phase
PHASE2
Sponsor
Zibo Municipal Hospital
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • SBRT combined with Tislelizumab followed by Tislelizumab
Locations (sample)
  • Zibo, Shandong, China|36.79056,118.06333

Key Eligibility Criteria

  • Age 18-75 years old, gender is not limited;
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • Patients with stage IIIB/C-IV non-squamous non-small cell lung cancer confirmed by cytology or histology;
  • Patients who have not received prior systemic therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →